IRMD vs. TMDX, SLNO, LIVN, ENOV, NVCR, WRBY, LMAT, CNMD, CDRE, and TNDM
Should you be buying Iradimed stock or one of its competitors? The main competitors of Iradimed include TransMedics Group (TMDX), Soleno Therapeutics (SLNO), LivaNova (LIVN), Enovis (ENOV), NovoCure (NVCR), Warby Parker (WRBY), LeMaitre Vascular (LMAT), CONMED (CNMD), Cadre (CDRE), and Tandem Diabetes Care (TNDM). These companies are all part of the "medical equipment" industry.
Iradimed vs.
TransMedics Group (NASDAQ:TMDX) and Iradimed (NASDAQ:IRMD) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, institutional ownership, earnings and analyst recommendations.
TransMedics Group presently has a consensus target price of $122.70, indicating a potential upside of 73.33%. Iradimed has a consensus target price of $72.00, indicating a potential upside of 35.95%. Given TransMedics Group's higher possible upside, equities analysts plainly believe TransMedics Group is more favorable than Iradimed.
TransMedics Group has a beta of 2.12, indicating that its share price is 112% more volatile than the S&P 500. Comparatively, Iradimed has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.
99.7% of TransMedics Group shares are held by institutional investors. Comparatively, 92.3% of Iradimed shares are held by institutional investors. 7.0% of TransMedics Group shares are held by insiders. Comparatively, 37.1% of Iradimed shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Iradimed has a net margin of 26.26% compared to TransMedics Group's net margin of 8.14%. Iradimed's return on equity of 24.12% beat TransMedics Group's return on equity.
In the previous week, TransMedics Group had 47 more articles in the media than Iradimed. MarketBeat recorded 53 mentions for TransMedics Group and 6 mentions for Iradimed. Iradimed's average media sentiment score of 1.24 beat TransMedics Group's score of 0.19 indicating that Iradimed is being referred to more favorably in the news media.
Iradimed has lower revenue, but higher earnings than TransMedics Group. Iradimed is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.
Iradimed received 147 more outperform votes than TransMedics Group when rated by MarketBeat users. Likewise, 65.40% of users gave Iradimed an outperform vote while only 59.26% of users gave TransMedics Group an outperform vote.
Summary
Iradimed beats TransMedics Group on 11 of the 19 factors compared between the two stocks.
Get Iradimed News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Iradimed Competitors List
Related Companies and Tools
This page (NASDAQ:IRMD) was last updated on 3/26/2025 by MarketBeat.com Staff
